ArticleTheranostics2018
A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Nanoparticles-assisted SELEX strategies for aptamer screening: a comprehensive review.Mikrochimica acta · 2026Review
- Advantages, applications, and future directions ofMolecular therapy. Nucleic acids · 2025Review
- Nanotechnology Applications in Breast Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy.Journal of hematology & oncology · 2024Review
- In situ cellular hitchhiking of nanoparticles for drug delivery.Advanced drug delivery reviews · 2024Review
- Aptamer‑based therapy for targeting key mediators of cancer metastasis (Review).International journal of oncology · 2022Review
- Aptamer-Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Nanotechnology-based products for cancer immunotherapy.Molecular biology reports · 2022Review
- Zinc-Loaded Black Phosphorus Multifunctional Nanodelivery System Combined With Photothermal Therapy Have the Potential to Treat Prostate Cancer Patients Infected With COVID-19.Frontiers in endocrinology · 2022Article
- A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells.iScience · 2021Article
- Nanoparticles Targeting Innate Immune Cells in Tumor Microenvironment.International journal of molecular sciences · 2021Review
- Functional Nucleic-Acid-Decorated Spherical Nanoparticles: Preparation Strategies and Current Applications in Cancer Therapy.Small science · 2021Article
- Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells.Frontiers in pharmacology · 2021Article
- Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?Molecular therapy. Nucleic acids · 2020Review
- Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy.Science translational medicine · 2020Article
- Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.Advanced materials (Deerfield Beach, Fla.) · 2020Review
- Tumor Targeted Nanocarriers for Immunotherapy.Molecules (Basel, Switzerland) · 2020Review
- Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.Journal of nanobiotechnology · 2020Article
- Zinc Ion-Stabilized Aptamer-Targeted Black Phosphorus Nanosheets for Enhanced Photothermal/Chemotherapy Against Prostate Cancer.Frontiers in bioengineering and biotechnology · 2020Article
- Lipoprotein-based drug delivery.Advanced drug delivery reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 2 countries.
Haoran LiuCollege of Materials Science and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing 100049, China.
Junhua MaiDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Jianliang ShenDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Joy WolframDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Zhaoqi LiDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Guodong ZhangDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Rong XuDepartment of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Yan LiDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Chaofeng MuDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Youli ZuDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.
Xin LiInstitute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA.
Ganesh L LokeshInstitute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA.
Varatharasa ThiviyanathanInstitute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA.
David E VolkInstitute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA.
David G GorensteinInstitute of Molecular Medicine and the Department of Nanomedicine and Biomedical Engineering, McGovern Medical School, The University of Texas Health Science Center at Houston, TX 77030, USA.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Zhongbo HuCollege of Materials Science and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing 100049, China.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Hospital Research Institute, Houston, TX 77030, USA.
Houston Methodist · USThe University of Texas Health Science Center at Houston · USMethodist Hospital · USCornell University · USMayo Clinic in Florida · USUniversity of Chinese Academy of Sciences · CNWeill Cornell Medicine · US
Funding
Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, RONGFU · 2016 to 2020
$9.3MTumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8MNCI NIH HHS R01 CA193880NCI NIH HHS U54 CA210181
Abstract
Aptamers have the potential to be used as targeting ligands for cancer treatment as they form unique spatial structures.
Indexed as
A549 CellsAnimalsAptamers, NucleotideCD11b AntigenCell Line, TumorDoxorubicinFemaleHumansMCF-7 CellsMiceMice, Inbred BALB CMice, NudeMyeloid-Derived Suppressor CellsPolyethylene GlycolsReceptors, ChemokineAptamers, NucleotideCD11b AntigenDoxorubicinliposomal doxorubicinPolyethylene GlycolsReceptors, Chemokineactive targetingDNA aptamerliposomemyeloid-derived suppressor cells (MDSCs)tumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.